Lushang Freda Pharmaceutical (600223.SS) Earnings Analysis
Lushang Freda Pharmaceutical (600223.SS) next reports earnings on 2026-08-26. It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E 32.83.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600223.SS next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
600223.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-03 | 0.05 CNY | n/a | n/a | n/a |
| 2025-04-25 | 0.05 CNY | n/a | n/a | n/a |
| 2025-03-22 | 0.07132 CNY | 0.11 CNY | -35.2% | Miss |
| 2024-10-28 | 0.0432 CNY | 0.07 CNY | -38.3% | Miss |
| 2024-08-23 | 0.0671 CNY | 0.09 CNY | -25.4% | Miss |
Beat rate: 0/3 (0%) over reported quarters with consensus data.
600223.SS valuation and analyst view
| Trailing P/E | 32.83 |
|---|---|
| Trailing EPS | 0.15889 CNY |
| Price / book | 1.35 |
| Dividend yield | 1.05% |
| Market cap | 5.48B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Lushang Freda Pharmaceutical (600223.SS)'s next earnings date?
Lushang Freda Pharmaceutical is next scheduled to report on 2026-08-26.
Did 600223.SS beat earnings last quarter?
Consensus estimate data was not available for 600223.SS's 2026-04-03 report.
What is 600223.SS's earnings track record?
Over the last 3 reported quarters with consensus data, 600223.SS beat estimates 0 times (0%).
What is 600223.SS's current P/E ratio and EPS?
600223.SS trades at a trailing P/E of 32.83 on trailing EPS of 0.15889024733561585 CNY.
What do analysts rate 600223.SS?
600223.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.